Concepedia

Sabeen Mekan

SM

Statistics

Publications

26

Citations

6.3K

H-Index

17

Active since

2004

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Memorial Sloan Kettering Cancer Center

Bristol-Myers Squibb (United States)

Institut Gustave Roussy

Roswell Park Comprehensive Cancer Center

Sabeen Mekan is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cancer therapeutics, and oncology.

Top concepts

Publications per year

2004–2025

26

Publications

26

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.5K citations · Full text

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 763 citations · Full text

, , +8

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

David Cella, Viktor Grünwald, Bernard Escudier et al. · The Lancet Oncology · 2019 · 251 citations · Full text

, , +8

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Meletios Α. Dimopoulos, Sagar Lonial, Keith A. Betts et al. · Cancer · 2018 · 139 citations · Full text

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 91 citations · Full text

1–5 of 26